135 related articles for article (PubMed ID: 32009076)
1. Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin.
Masuda D; Yamashita S
J Atheroscler Thromb; 2020 Jul; 27(7):637-638. PubMed ID: 32009076
[No Abstract] [Full Text] [Related]
2. Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease.
Sawada T; Uzu K; Hashimoto N; Onishi T; Takaya T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H
J Atheroscler Thromb; 2020 Jul; 27(7):644-656. PubMed ID: 31631099
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice.
Ganbaatar B; Fukuda D; Shinohara M; Yagi S; Kusunose K; Yamada H; Soeki T; Hirata KI; Sata M
Eur J Pharmacol; 2020 May; 875():173040. PubMed ID: 32114052
[TBL] [Abstract][Full Text] [Related]
4. Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
Striepe K; Jumar A; Ott C; Karg MV; Schneider MP; Kannenkeril D; Schmieder RE
Circulation; 2017 Sep; 136(12):1167-1169. PubMed ID: 28923906
[No Abstract] [Full Text] [Related]
5. Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon.
Ren DY; Zhang Y
Curr Drug Targets; 2018; 19(9):1051-1057. PubMed ID: 29848274
[TBL] [Abstract][Full Text] [Related]
6. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Heise T; Bizzotto R; Mari A; Pieber TR; Muscelli E
Diabetes; 2016 May; 65(5):1190-5. PubMed ID: 26861783
[TBL] [Abstract][Full Text] [Related]
7. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
[TBL] [Abstract][Full Text] [Related]
9. Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.
Cooper ME; Inzucchi SE; Zinman B; Hantel S; von Eynatten M; Wanner C; Koitka-Weber A
Am J Kidney Dis; 2019 Nov; 74(5):713-715. PubMed ID: 31255334
[No Abstract] [Full Text] [Related]
10. Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study.
Suhrs HE; Nilsson M; Bové KB; Zander M; Prescott E
PLoS One; 2022; 17(2):e0263481. PubMed ID: 35148357
[TBL] [Abstract][Full Text] [Related]
11. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
Trujillo JM; Nuffer WA
Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
[TBL] [Abstract][Full Text] [Related]
12. Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress.
Trnovska J; Svoboda P; Pelantova H; Kuzma M; Kratochvilova H; Kasperova BJ; Dvorakova I; Rosolova K; Malinska H; Huttl M; Markova I; Oliyarnyk O; Melcova M; Skop V; Mraz M; Stemberkova-Hubackova S; Haluzik M
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638943
[TBL] [Abstract][Full Text] [Related]
13. Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).
Jürgens M; Schou M; Hasbak P; Kjær A; Wolsk E; Zerahn B; Wiberg M; Brandt NH; Gæde PH; Rossing P; Faber J; Inzucchi S; Gustafsson F; Kistorp CM
BMJ Open; 2019 Nov; 9(11):e029098. PubMed ID: 31780586
[TBL] [Abstract][Full Text] [Related]
14. Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans.
Ryan SPP; Newman AA; Wilburn JR; Rhoades LD; Trikha SRJ; Godwin EC; Schoenberg HM; Battson ML; Ewell TR; Luckasen GJ; Biela LM; Melby CL; Bell C
Nutrients; 2020 Feb; 12(2):. PubMed ID: 32085394
[TBL] [Abstract][Full Text] [Related]
15. Impact of EMPA-REG OUTCOME
Naing S; Poliyedath A; Khandelwal S; Sigala T
Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.
Kurozumi A; Okada Y; Shimokawa M; Goshima Y; Otsuka T; Narisawa M; Torimoto K; Tanaka Y
Diabetes Technol Ther; 2019 Jul; 21(7):385-392. PubMed ID: 31210529
[No Abstract] [Full Text] [Related]
17. Marked Hypertriglyceridemia in a Patient with type 2 Diabetes Receiving SGLT2 Inhibitors.
Senoo M; Tone A; Imai Y; Watanabe S; Kaneto M; Shimomura Y; Teshigawara S; Nakatou T
Acta Med Okayama; 2021 Feb; 75(1):103-107. PubMed ID: 33649621
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin and Major Renal Outcomes in Heart Failure.
Packer M; Butler J; Zannad F; Pocock SJ; Filippatos G; Ferreira JP; Brueckmann M; Jamal W; Zeller C; Wanner C; Anker SD;
N Engl J Med; 2021 Oct; 385(16):1531-1533. PubMed ID: 34449179
[No Abstract] [Full Text] [Related]
19. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.
Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):211-223. PubMed ID: 27817207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]